156 related articles for article (PubMed ID: 29097444)
1. RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.
Howell A; Ashcroft L; Fallowfield L; Eccles DM; Eeles RA; Ward A; Brentnall AR; Dowsett M; Cuzick JM; Greenhalgh R; Boggis C; Motion J; Sergeant JC; Adams J; Evans DG
Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):58-66. PubMed ID: 29097444
[No Abstract] [Full Text] [Related]
2. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
3. The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer.
von Minckwitz G; Loibl S; Jackisch C; Paepke S; Nestle-Kraemling C; Lux MP; Maass N; Schmutzler R; du Bois A; Wallwiener D; Vescia S; Budischewski K; Kaufmann M
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2141-9. PubMed ID: 21795500
[TBL] [Abstract][Full Text] [Related]
4. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
[TBL] [Abstract][Full Text] [Related]
6. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer.
Eng-Wong J; Orzano-Birgani J; Chow CK; Venzon D; Yao J; Galbo CE; Zujewski JA; Prindiville S
Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1696-701. PubMed ID: 18583470
[TBL] [Abstract][Full Text] [Related]
7. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS
J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538
[TBL] [Abstract][Full Text] [Related]
8. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
Jonat W
Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
[TBL] [Abstract][Full Text] [Related]
9. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
10. Add-back therapy with GnRH analogues for uterine fibroids.
Moroni RM; Martins WP; Ferriani RA; Vieira CS; Nastri CO; Candido Dos Reis FJ; Brito LG
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010854. PubMed ID: 25793972
[TBL] [Abstract][Full Text] [Related]
11. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Knauer M; Moik M; Jakesz R; Seifert M; Taucher S; Bjelic-Radisic V; Balic M; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Selim U; Fitzal F; Hochreiner G; Wette V; Sevelda P; Ploner F; Bartsch R; Fesl C; Greil R;
Ann Oncol; 2015 Feb; 26(2):313-20. PubMed ID: 25403582
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials.
Salazar AS; Rakhmankulova M; Simon LE; Toriola AT
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33554041
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of breast cancer.
Thomsen A; Kolesar JM
Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189
[TBL] [Abstract][Full Text] [Related]
15. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
17. Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer.
Noguchi S; Kim HJ; Jesena A; Parmar V; Sato N; Wang HC; Lokejaroenlarb S; Isidro J; Kim KS; Itoh Y; Shin E
Breast Cancer; 2016 Sep; 23(5):771-9. PubMed ID: 26350351
[TBL] [Abstract][Full Text] [Related]
18. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
20. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
